Takeda completes new German manufacturing facility

19 June 2017

Japan’s largest drugmaker, Takeda Pharmaceutical (TYO: 4502) says it has now completed the construction of new manufacturing facilities at its site in Oranienburg, Germany, aiming to deliver the firm's high-quality medicines to more patients in a timely manner as well as further address patients' needs.

The new facility was built at a total cost of around 100 million euros ($112 million) and is scheduled to begin operating at the end of 2017. The state of Brandenburg and the German federal government each contributed half of the approximately 23 million euros in subsidies for the plant expansion.

The importance of this investment was evidenced by the participation in the inauguration ceremonies of the Federal Chancellor of Germany, Angela Merkel, Japan's Ambassador to Germany, Takeshi Yagi, the Federal State Prime Minister of Brandenburg, Dietmar Woidke and Takeda’s president and chief executive, Christophe Weber.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK